Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer

Go back to Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
(NASDAQ: ALLR) Delayed: 1.36 -0.07 (4.9%)
Previous Close $1.43    52 Week High
Open $1.43    52 Week Low
Day High $1.51    P/E N/A 
Day Low $1.27    EPS
Volume 153,233